BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.